

WHAT IS CLAIMED IS

1. A composition comprising one or more peptides from any of Tables 11-29.
2. A composition comprising nucleic acids encoding one or more peptides from any of Tables 11-29.
3. The composition of claim 1 or 2, wherein at least one of the one or more peptides is an HTL epitope.
4. The composition of claim 1 or 2, wherein at least one of the one or more peptides is a CTL epitope.
5. The composition of claim 4, further comprising an HTL epitope.
6. The composition of claim 1 or 2, further comprising a spacer molecule.
7. The composition of claim 1 or 2, further comprising a carrier.
8. The composition of claim 1 or 2, further comprising an MHC targeting sequence.
9. The composition of claim 1 or 2, further comprising a lipid.
10. The composition of claim 1 or 2, wherein the one or more peptides are incorporated as part of a liposome.
11. The composition of claim 1 or 2, wherein at least one of the one or more peptides is a heteropolymer.
12. The composition of claim 1 or 2, wherein at least one of the one or more peptides is a homopolymer.
13. The composition of claim 1 or 2, wherein at least one of the one or more peptides is a peptide from an antigen selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B virus (HBV) antigen, hepatitis C

virus (HCV) antigen, malignant melanoma antigen (MAGE), Epstein Barr virus, human immunodeficiency type-1 (HIV-1), human immunodeficiency type-2 (HIV-2), papilloma virus, Lassa virus, mycobacterium tuberculosis (MT), p53, murine p53 (mp53), CEA, HER2/neu, and tyrosine kinase related protein (TKP).

14. A pharmaceutical composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim 1 or 2.
15. A vaccine composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim 1 or 2.
16. The use of the composition of any of claims 1, 2, 14 or 15, wherein the composition is a prophylactic composition for the prevention of viral infection or cancer.
17. The use of the composition of any one of claims 1, 2, 14 or 15, wherein the composition is a therapeutic composition for the treatment of viral infection or cancer.
18. A diagnostic reagent comprising the composition of claim 1 or 2.
19. The use according to claim 17, for the treatment of prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV or chondyloma acuminatum.